Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded...

Area of Science:

• Proteomics
• Molecular diagnostics
• Cancer research

Background:

• Personalized cancer medicine relies on molecular tumor analysis.
• Current protein quantification methods face limitations like sample issues and batch effects.
• Digital protein quantification offers a promising avenue for clinical applications.

Purpose of the Study:

• To develop and validate a novel multiplexed DNA-labeled antibody platform for digital protein quantification.
• To assess the platform's reproducibility, comparability to existing assays, and applicability to clinical samples.
• To explore the platform's utility in identifying molecular subtypes of breast cancer.

Main Methods:

• Development of a multiplexed DNA-labeled antibody platform for protein expression analysis from lysate samples.
• Rigorous antibody validation and platform testing across multiple protocols (nitrocellulose, plate-based).
• Comparison with orthogonal proteomic assays (e.g., Reverse-Phase Protein Array) and application to breast cancer patient samples.

Main Results:

• The platform demonstrates high reproducibility with no observed batch effects.
• Protein quantification results are comparable to established proteomic assays.
• The platform successfully profiled breast cancer patient samples, aiding in molecular subtyping.

Conclusions:

• The novel DNA-labeled antibody platform offers a robust and reproducible method for digital protein quantification.
• This technology has the potential to overcome current limitations in protein expression analysis for clinical applications.
• The platform shows promise for advancing cancer biology understanding and clinical translation, including therapeutic selection and subtyping.